Skip to main content
SpringerLink
Log in

Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The objective of this work was to develop matrix sustained-release tablets of highly water-soluble tramadol HCl using natural gums (xanthan [X gum] and guar [G gum]) as cost-effective, nontoxic, easily available, and suitable hydrophilic matrix systems compared with the extensively investigated hydrophilic matrices (ie, hydroxypropyl methylcellulose [HPMC]/carboxymethyl cellulose [CMC] with respect to in vitro drug release rate) and hydration rate of the polymers. Matrix tablets of tramadol (dose 100 mg) were produced by direct compression method. Different ratios, of 100∶0, 80∶20, 60∶40, 20∶80, 0∶100 of G gum (or X):HPMC, X gum:G gum, and triple mixture of these polymers (G gum, X gum, HPMC) were applied. After evaluation of physical characteristics of tablets, the dissolution test was, performed in the phosphate buffer media (pH 7.4) up to 8 hours. Tablets with only X had the highest mean dissolution time (MDT), the least dissolution efficiency (DE8%), and released the drug following a zero-order model via swelling, diffusion, and erosion mechanisms. Guar gum alone could not efficiently control the drug release, while X and all combinations of natural gums with HPMC could retard tramadol HCl release. However, according to the similarity factor (f 2), pure HPMC and H8G2 were the most similar formulations to Topalgic-LP as the reference standard.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Altman RA, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905–1915.

    Article  Google Scholar 

  2. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.

    Article  CAS  PubMed  Google Scholar 

  3. Medical Economics Staff. Physicians’ Desk Reference. Greenwood Village, CO: Thomson Micromedex; 2003.

    Google Scholar 

  4. Raber M, Hoffman S, Junge K, Momberger H, Kuhn D. Analgesic efficacy and tolerability of tramadol 100 mg sustained release capsules in patients with moderate to severe chronic low back pain. Clin Drug Invest. 1999;17:415–423.

    Article  CAS  Google Scholar 

  5. Malonne H, Coffiner M, Fontaine D. et al. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther. 2005;30:113–120.

    Article  CAS  PubMed  Google Scholar 

  6. Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1774–1782.

    Article  CAS  PubMed  Google Scholar 

  7. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59–71.

    Article  CAS  PubMed  Google Scholar 

  8. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech. 2003;4:E31.

    Article  PubMed  Google Scholar 

  9. Obaidat AA, Obaidat RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm. 2001;52:231–235.

    Article  CAS  PubMed  Google Scholar 

  10. Malonne H, Fontaine J, Moes A. In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water. Biol Pharm Bull. 2000;23:627–631.

    Article  CAS  PubMed  Google Scholar 

  11. Zhang ZY, Ping QN, Xiao B. Microencapsulation and characterization of tramadol-resin complexes. J Control Release. 2000;66:107–113.

    Article  CAS  PubMed  Google Scholar 

  12. Krishnaiah YSR, Karthikeyan RS, Satyanarayana V. A three-layer guar gum matrix tablet for oral controlled delivery of highly soluble metoprolol tartrate. Int J Pharm. 2002;241:353–366.

    Article  CAS  PubMed  Google Scholar 

  13. Krishnaiah YS, Karthikeyan RS, Gouri Sankar V, Satyanarayana V. Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. J Control Release. 2002;81:45–56.

    Article  CAS  PubMed  Google Scholar 

  14. Pai VB, Khan SA. Gelation and rheology of xanthan/enzyme-modified guar blends. Carbohydrate Polym. 2002;49:207–216.

    Article  CAS  Google Scholar 

  15. Castro IA, Tirapegui J, Benedicto ML. Effects of diet supplementation with 3 soluble polysaccharides on serum lipid levels of hypercholesterolemic rats. Food Chem. 2003;80:323–330.

    Article  CAS  Google Scholar 

  16. Durig T, Fassihi R. Guar-based monolithic matrix systems: effect of ionizable and nonionizable substances and exipients on gel dynamics and release kinetics. J Control Release. 2002;80:45–56.

    Article  CAS  PubMed  Google Scholar 

  17. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 2001;220:77–83.

    Article  CAS  PubMed  Google Scholar 

  18. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.

    Article  CAS  Google Scholar 

  19. Costa P, Manuel J. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133.

    Article  CAS  PubMed  Google Scholar 

  20. Banakar UV. Pharmaceutical Dissolution Testing. New York, NY: Marcel Dekker Inc; 1992.

    Google Scholar 

  21. Gohel MC, Panchal MK. Novel use of similarity factors f 2 and sd for the development of diltiazem HCl modified-release tablets using a 32 factorial design. Drug Dev Ind Pharm. 2002;28: 77–87.

    Article  CAS  PubMed  Google Scholar 

  22. FDA Guidance for Industry. Dissolution Testing of Immediate and Modified Release of Solid Oral Dosage Forms. Rockville, MD: National Press Office. FDA Guidance for Industry No. 32.

  23. Bhalla HL, Sanzgiri YD. An improved controlled release tablet of sulbutamol sulphate. Indian J Pharm Sci. 1987;49:22–25.

    CAS  Google Scholar 

  24. Salsa T, Veiga G, Pina ME. Oral controlled-release dosage forms. I. cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:292–938.

    Article  Google Scholar 

  25. Aulton ME. Pharmaceutics: The Science of Dosage Form Design. London, UK: Churchill Livingstone; 2002.

    Google Scholar 

  26. Varshosaz J, Tavakoli N, Eram SA. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Deliv. In press.

  27. Lu MF, Woodward L, Borodkin S. Xanthan gum and alginate based controlled release theophyllin formulations. Drug Dev Ind Pharm. 1991;17:1987–2004.

    Article  CAS  Google Scholar 

  28. Cox PJ, Khan KA, Munday DL, Sujja-areevath J. Development and evaluation of a multiple-unit oral sustained-release dosage form for S(+)-ibuprofen: preparation and release, kinetics. Int J Pharm. 1999;193:73–84.

    Article  CAS  PubMed  Google Scholar 

  29. Munday DL, Cox PJ. Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms. Int J Pharm. 2000;203:179–192.

    Article  CAS  PubMed  Google Scholar 

  30. Ughini F, Andreazza IF, Ganter JLMS, Bresolin TMB. Evaluation of xanthan and highly substituted galactomannan from M Scabrella as a sustained release matrix. Int J Pharm. 2004;271:197–205.

    Article  CAS  PubMed  Google Scholar 

  31. Al-Saidian SM, Krishnaiah YSR, Patro SS, Satyanaryana V. In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. AAPS PharmSciTech. 2005;6:E5.

    Google Scholar 

  32. Altaf SA, Yu K, Parasrampuria J, Friend DR. Guar gum-based sustained release diltiazem. Pharm Res. 1998;15:1196–1201.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

    Jaleh Varshosaz, Naser Tavakoli & Fatemeh Kheirolahi

Authors
  1. Jaleh Varshosaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naser Tavakoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Kheirolahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaleh Varshosaz.

Additional information

Published: March 17, 2006

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varshosaz, J., Tavakoli, N. & Kheirolahi, F. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 7, 24 (2006). https://doi.org/10.1208/pt070124

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/pt070124

Keywords

Search

Navigation